Jeisys Medical Inc.

2Q 2022 Earnings

Jeisys

Disclaimer

Financial information contained in this document is based on consolidated K-IFRS that have not been audited by an independent auditor.

Therefore, the information and financial data of Jeisys Medical and its subsidiaries (the "Company", or "Jeisys Medical") contained in this document are subject to change upon an independent auditor's audit.

The company does not make any representation or accept liability, as to the accuracy or completeness of the information contained in this material.

The format and contents of this document are subject to change for future filings and reports. Jeisys Medical is not liable for providing future updates on all figures included in this document.

Therefore, this presentation contained herein should not be utilized for any legal purposes in regard to investors' investment results. The company hereby expressly disclaims any and all liability for any loss or damage resulting from the investors' reliance on the information contained here in.

Summary of 2Q 2022 earnings

Jeisys

- The highest ever quarterly sales reached [2Q 2022 30.8 bn / YoY 59.9%]
- The highest ever quarterly operating profit reached [2Q 2022 9.0bn / YoY 52.8%]

Unit : KRW million

Consolidated based on K-IFRS	2021		2022		YoY	
	2Q	Accumulated	2Q	Accumulated	2Q	Accumulated
Sales	**19,239**	**36,497**	**30,770**	**56,104**	**59.9%**	**53.7%**
Cost of Goods sales	5,913	10,626	10,056	17,694	70.0%	66.5%
Gross profit	**13,326**	**25,871**	**20,715**	**38,411**	**55.4%**	**48.5%**
SG&A Expense	7,460	15,073	11,759	20,906	57.5%	38.7%
Operating profit	**5,865**	**10,798**	**8,955**	**17,504**	**52.8%**	**62.2%**
Net profit before Income tax (Note 1)	5,747	90	9,358	17,758	63.0%	19,687.9%
Net profit (Note 1)	**5,634**	**-669**	**7,385**	**13,897**	**30.6%**	**turnaround**
EBITDA	**6,413**	**11,920**	**9,704**	**18,961**	**51.3%**	**59.1%**

Note1) 1Q 2021_ Other losses (Merger Cost KRW 10.569 million)

Sales Classification by Product Portfolio

Jeisys

- Continuous sales growth of RF devices by expanding the export in the global market.
- Sales growth of consumables by increasing in device sales and number of aesthetic procedures.

Consumables

Cartridge

Tip





RF

POTENZA™

INTRAcel PRO™



IPL / LASER

cellec v system

TRI-BEAM Premium™



HIFU



LinearZ

LinearFirm



Sales by product portfolio

Jeisys

- Due to high demand for POTENZA, steady sales growth of RF devices.

- Change the growing trend after the launch of a new device (LinearZ) at the end of June 2022

Unit : KRW million

Consolidated based on K-IFRS	2021		2022		YoY	
	2Q	Accumulated	2Q	Accumulated	2Q	Accumulated
Sales	**19,239**	**36,497**	**30,770**	**56,104**	**59.9%**	**53.7%**
Device	9,128	18,510	17,023	31,446	86.5%	69.9%
Consumable	9,413	16,673	13,120	23,357	39.4%	40.1%
Others	699	1,314	628	1,302	-10.2%	-1.0%

Device

- **HIFU** (YoY -6%) : - Due to deferred demand ahead of the release of a new device (LinearZ), sales decreased.
  - Change the growing trend after the launch of LinearZ at end of June 2022
- **RF** (YoY 182%) : - POTENZA ODM increased due to strong RF demand trend in the global market.
  - Continuous growing trend in Korea and Japan.
- **LASER** (YoY 48%) : Overseas sales of Edge ONE increased.
- **IPL** (YoY 5%) : Overseas sales of Cellec and other devices increased.

Consumables

- **Cartridge** (YoY 60%) : As increasing in number of aesthetic procedures through the existing devices of LinearFirm (UltracelQ+), Sales increased.
- **Tip** (YoY 75%) : As expanding order for consumables of POTENZA which sold last year, high demand for multi-functional tips.

Note 1) Growth rate : Based on number of sales

Overseas business capabilities

Jeisys

- Entering to more than 60 countries and the export growth was 60.2% in the last 3 years

- Continue expanding the export share centered in Japan and North America (1H2022 86.9%)

Europe
- Expanded ODM through Cynosure (POTENZA)
- Expanded sales channel (HIFU, LASER ,etc.)

China
- Plan business advance through partnership

Japan
- Acquired the market share of HIFU devices
- Constant growth in POTENZA
- Sales in main devices from Cynosure

North America
- Expanded ODM through Cynosure (POTENZA)
- Plan business advance

SE Asia
- Expanded ODM through Cynosure (POTENZA)
- Expanded Sales Channel (HIFU, LASER ,etc.)

Australia
- Enter in collaboration with Cynosure (POTENZA, HIFU)
- Strengthens business capabilities with a local subsidiary

Latin America
- Finding partnership through a strategic investment
- Expanded Sales Channel

The trend of export

Unit: KRW100million



Sales by Regional

Jeisys

- Continue sales growth of overseas [overseas sales accounted for 86.9% in 1H2022]

- Expanding the proportion of export centered in the global market with POTENZA

Unit : KRW million

Consolidated based on K-IFRS	2021		2022		YoY	
	2Q	Accumulated	2Q	Accumulated	2Q	Accumulated
Sales	**19,239**	**36,497**	**30,770**	**56,104**	**59.9%**	**53.7%**
Domestic	2,848	5,308	3,894	7,327	36.7%	38.0%
Overseas	16,391	31,189	26,876	48,777	64.0%	56.4%

Domestic

・**HIFU** : - Sales decreased due to deferred demand ahead of the release of a new device
- Change the growing trend after the launch of LinearZ at the end of June 2022

・**RF** : With the growth of RF market, sales in POTENZA continued to grow steadily. (YoY 31%)

・**Consumables** : Cartridge (YoY 111%), Tip (YoY 92%)

Overseas

・**Japan** : - HIFU : · Sales decreased due to deferred demand ahead of the release of a new device
· Change the growing trend after the launch of Ultracel[Zi]
- POTENZA : Expanded by entering aesthetic clinics (YoY 167%)
- Consumables : Cartridge (YoY 82%), Tip (YoY 440%)

・**Cynosure** : - POTENZA : Increased the quantity of ODM as higher demand (YoY 511%)
- Consumables : High demand for multi-functional tips (YoY 91%)

Note 1) Growth rate : Based on number of sales

Profit and Loss

Jeisys

- Reached KRW 9bn in operating profit in 2Q2022 [OPM 29%]

- Improved incentive provision and R&D expenses

Unit : KRW million

Consolidated based on K-IFRS	2021		2022		YoY	
	2Q	Accumulated	2Q	Accumulated	2Q	Accumulated
Cost of Goods Sold	5,913	10,626	10,056	17,694	70.0%	66.5%
Gross Profit	13,326	25,871	20,715	38,411	55.4%	48.5%

・The ratio of Cost of Goods sold in 2Q2022 : the raw material cost increases and the incentive provisions for production employees (YoY 2%p)

Unit : KRW million

Consolidated based on K-IFRS	2021		2022		YoY	
	2Q	Accumulated	2Q	Accumulated	2Q	Accumulated
SG&A Expense	7,460	15,073	11,759	20,906	57.5%	38.7%
Operating Profit	5,865	10,798	8,955	17,504	52.8%	62.2%

・SG&A Expense ratio : Improved by sales growth (YoY 0.6%p)

・SG&A Expense : - Increased labor costs by reflecting incentive provisions for employees
- Increased R&D expense and commission fee for the launch of a new device

Unit : KRW million

Consolidated based on K-IFRS	2021		2022		YoY	
	2Q	Accumulated	2Q	Accumulated	2Q	Accumulated
Net Profit	5,634	-669	7,385	13,897	30.6%	turnaround

・Other Losses (Accumulated): Merger Cost (KRW10,569mn) in 1Q2021

GROW YOUR BUSINESS WITH
JEISYS MEDICAL INC.,

APPENDIX

Jeisys

RF (POTENZA™)

Jeisys

Enhance the effects of RF procedure and provide customized procedures with cutting edge tip technology

Enhance the efficacy by customized procedures

Multiple procedures by selecting combinations to meet the indications such as two frequencies of monopolar and bipolar

1Mhz(low density)
- Mono-Polar: Wide area
- BI-Polar: Narrow area

2Mhz(high density)
- Mono-Polar: Wide area
- BI-Polar: Narrow area

Various procedures by skin condition

1Mhz



Area with low density

2Mhz



Area with high density

Mono-Polar



Generate wide procedural area by diluted density at the center of tips

BI-Polar



Form the procedural area at the locations of both electrodes (procedural target between two electrodes)

Tip

Pumping Tip

Structure	Function	Efficacy
Design the solution to be inserted into the hole of the tip when the tip is released	Insert the solution to the adjusted space by RF energy accurately	Independent parameter RF energy + inject the drug simultaneously = enhanced efficacy

Non-invasive Tip

SFA Tip

DDR Tip

DIA Tip

HIFU (LinearZ) - History

Jeisys

2014	2018	2022
1st Generation Dot Type HIFU	2nd Generation Linear Type HIFU	3rd Generation Linear & Dot **Adjustable Depth & Mode in a single cartridge**

ULTRAcel



- 3-in-1 System: Grid RF, RF Microneedle, HIFU
- The fastest HIFU treatment
- Multiple layer treatment for multiple indications

LINEAR FIRM

- Improved procedural speed and area with linear cartridge compared to those with dot type
- Dot Cartridge (300shots/8mins)
  Linear Cartridge (300shots/3mins)
  The fastest treatment time

LINEARZ

- Adjustable depth and mode (Linear & Dot) in one cartridge
  ("Lifting & Tightening for the skin on thighs"
  - KFDA approved)
- Improved procedural speed and safety by automatic depth control

HIFU (Linear Z) – Cartridge_1

Jeisys

Improved procedural speed and safety by automatic depth control

- Convenience of treatment for patients with the fastest treatment time

*The fastest treatment time than Linearfirm (Linearfirm -> less than 3mins, Linear Z ->1.8mins / 300 shots)



Dot Mode	Speed	Linear Mode
Approx. 1.47 sec	**1 Shot**	Approx. 0.37 sec
Less than 25.4 min (Auto interval 0.1s)	**1,000 Shot**	Less than 6.09 min (Auto interval 0.1s)

HIFU (Linear Z) – Cartridge_2

Jeisys

Adjustable Depth and Mode (Linear & Dot) in one cartridge

- Only 4 Cartridges enable convenient treatment
- Without replacing cartridge, it enables convenient treatment
- One Cartridge allows multi layer (Epidermis, Dermis, Subcutaneous layer) treatment

Mode

① Dot
② Linear

*Available to mode (Linear & Dot) in all type of Cartridges

Type	A(Basic)	B(Essential)	C(Core)	D(Contour)
				
DEPTH & MODE	• 2.0 mm DOT • 2.0 mm LINEAR • 3.0 mm DOT • 3.0 mm LINEAR	• 1.5 mm DOT • 1.5 mm LINEAR • 2.0 mm DOT • 2.0 mm LINEAR • 3.0 mm DOT • 3.0 mm LINEAR	• 4.5 mm DOT • 4.5 mm LINEAR	• 9.0 mm DOT • 9.0 mm LINEAR • 11.0 mm DOT • 11.0 mm LINEAR • 13.0 mm DOT • 13.0 mm LINEAR

Facial type
Body type

Global Partnership

Jeisys

Accelerate global market penetration by collaborating with Cynosure

Jeisys CYNOSURE®

Agreement in June 2019

Expansion of collaborative areas starting with ODM Supply

Planning
- Planning new devices
- Discussion to improve and innovate the existing devices

R&D
- Co-developing devices to further penetrate the global market

Product Supply
- Continuous expansion of supply items such as HIFU/RF devices, Consumables, etc.

Network
- Co-entrance to the global market (Asia, Latin America, etc.)

Shareholders

Jeisys

Shareholder Status

Rating Classification	Shareholder Name	Number of Shares	Stake Percentile
Largest Shareholders	Dong Hwan Kang	17,972,844	25.21%
Affiliated Persons	Myeong Hoon Lee	3,859,127	5.41%
	Kang Lak Lee	90,000	0.13%
	Tae Hwan Kim	9,000	0.01%
	Il kwon Kang	2,000	0.00%
Treasury Shares	Jeisys Medical Inc	131,048	0.18%
Holding at least 5%	National Pension Service of Korea	3,694,047	5.18%
Other shareholders	-	45,541,406	63.87%
Issued Shares	**-**	**71,299,472**	**100.00%**

Note 1) As of June 30, 2022

Financial Information

Jeisys

Consolidated Statements of Financial Position

Unit: KRW million

field	2019	2020	2021	1H2022
Current assets	19,725	28,264	54,173	67,776
Non-current assets	8,086	10,903	19,886	27,686
Total assets	**27,810**	**39,167**	**74,059**	**95,462**
Current liabilities	23,358	12,918	24,027	29,097
Non-current liabilities	13,495	9,290	2,379	3,995
Total liabilities	**36,853**	**22,208**	**26,405**	**33,092**
Issued capital	2,048	3,043	7,130	61,887
Capital Surplus	2,769	20,200	26,849	7,130
Elements of other Stockholder's equity	76	341	6,367	26,421
Other comprehensive income/loss accumulated amount	54	-38	-126	8,039
Retained earnings	-13,989	-6,587	6,865	-526
Non-controlling interests	-	-	568	20,823
Total equity	**-9,043**	**16,959**	**47,654**	**483**

Note 1) Consolidated Financial results based on K-IFRS

Consolidated Statements of Income

Unit: KRW million

field	2019	2020	2021	1H2022
Sales	**35,149**	**47,829**	**81,296**	**56,104**
Cost of Goods Sold	12,829	14,090	24,649	17,694
Gross Profit	22,320	33,739	56,647	38,411
SG&A Expense	19,484	22,709	33,042	20,900
Operating Profit	**2,836**	**11,030**	**23,604**	**17,510**
Finance Income	1,261	1,965	1,045	1,447
Finance Costs	2,067	4,217	897	1,079
Other Gains	347	141	208	47
Other Losses	1,055	705	10,866	160
Profit before tax	1,321	8,215	13,093	17,765
Income tax	130	1,064	-667	3,892
Profit from discontinued operations	-89	391	-268	-
Net Profit	**1,102**	**7,543**	**13,493**	**13,873**